Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Elizabeth Stephansens vei 15, 1433, Ås, Norway.
Department of Preclinical Sciences and Pathology, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Elizabeth Stephansens vei 15, 1433, Ås, Norway.
Acta Vet Scand. 2021 Nov 3;63(1):41. doi: 10.1186/s13028-021-00608-9.
Despite decades of research, the early phases of metastatic development are still not fully understood. Canine osteosarcoma (OS) is a highly aggressive cancer, with a high metastatic rate (> 90%), despite a low overt metastatic prevalence at initial diagnosis (< 15%). Canine OS is generally regarded as a good clinically relevant model for human OS. The aim of this hypothesis-generating study was to evaluate a method to detect pulmonary micrometastases and study their prevalence in dogs with OS without macroscopic metastases. We prospectively enrolled dogs with OS that received no cancer-specific treatment (n = 12) and control dogs without cancer (n = 2). Dogs were necropsied and sampled immediately after euthanasia. The OS dogs were classified as having macroscopic metastases (n = 2) or not (n = 10). We immunohistochemically stained one tissue sample from each of the seven lung lobes from each dog with a monoclonal antibody (TP-3) to identify micrometastases (defined as clusters of 5-50 tumour cells), microscopic metastases (> 50 tumour cells) and TP-3 positive single cells (< 5 tumour cells).
We showed that pulmonary micrometastases easily overseen on routine histology could be detected with TP-3. Pulmonary micrometastases and microscopic metastases were present in two dogs with OS without macroscopic metastases (20%). Micrometastases were visualised in three (43%) and four (57%) of seven samples from these two dogs, with a mean of 0.6 and 1.7 micrometastases per sample. Microscopic metastases were present in one (14%) and four (57%) of seven samples from the same two dogs, with a mean of 0.14 and 1.0 microscopic metastases per sample. There were four (57%) and two (29%) samples with neither microscopic metastases nor micrometastases for each of these two dogs. The prevalence of pulmonary micrometastases (20%) was significantly lower than expected (> 90%) based on commonly expected metastatic rates after amputation (P < 0.0001). There was no statistically significant difference in the number of TP-3 positive single cells in between groups (P = 0.85).
Pulmonary micrometastases could be detected with TP-3 immunohistochemistry in a subset of dogs with OS before macroscopic metastases had developed. We propose that dogs with spontaneous OS represent clinically relevant models to study early micrometastatic disease.
尽管经过了几十年的研究,转移性疾病的早期阶段仍未被完全理解。犬骨肉瘤(OS)是一种高度侵袭性的癌症,转移率很高(>90%),尽管在初始诊断时明显转移的患病率较低(<15%)。犬 OS 通常被认为是研究人类 OS 的良好临床相关模型。本假设生成研究的目的是评估一种检测肺微转移的方法,并研究无肉眼转移的 OS 犬中微转移的患病率。我们前瞻性地招募了未接受癌症特异性治疗的 OS 犬(n=12)和无癌症的对照犬(n=2)。犬在安乐死后立即进行尸检和采样。OS 犬被分为有肉眼转移(n=2)或无肉眼转移(n=10)。我们用单克隆抗体(TP-3)对每只犬的七个肺叶中的一个组织样本进行免疫组织化学染色,以识别微转移(定义为 5-50 个肿瘤细胞簇)、显微镜下转移(>50 个肿瘤细胞)和 TP-3 阳性的单个细胞(<5 个肿瘤细胞)。
我们表明,TP-3 可检测到常规组织学上容易忽略的肺微转移。两只有无肉眼转移的 OS 犬(20%)存在肺微转移和显微镜下转移。这两只犬的七个样本中有三个(43%)和四个(57%)可见微转移,每个样本的平均微转移数为 0.6 和 1.7。同一两只犬的七个样本中有一个(14%)和四个(57%)存在显微镜下转移,每个样本的平均显微镜下转移数为 0.14 和 1.0。这两只犬的每个样本均有四个(57%)和两个(29%)既无显微镜下转移也无微转移。根据截肢后通常预期的转移率(>90%),肺微转移的患病率(20%)明显低于预期(P<0.0001)。两组间 TP-3 阳性单个细胞的数量无统计学差异(P=0.85)。
在 OS 犬出现肉眼转移之前,我们可以通过 TP-3 免疫组化检测到部分犬的肺微转移。我们建议,自发性 OS 犬代表了研究早期微转移疾病的临床相关模型。